Journal article
Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study
CLB Ho, EK Chowdhury, M Breslin, J Doust, CM Reid, LMH Wing, MR Nelson, LJ Beilin, GL Jennings, CI Johnston, GJ Macdonald, JE Marley, JJ McNeil, TO Morgan, P Ryan, MJ West
Journal of Clinical Lipidology | ELSEVIER SCIENCE INC | Published : 2019
Abstract
Background: There is currently insufficient evidence to support the use of lipid-lowering drug treatment (LLT) for primary prevention of cardiovascular disease (CVD) in the elderly. Objectives: We examined the relationship of early initiation of LLT with short- and long-term all-cause and CVD mortality in persons older than 65 years in this post hoc study from the Second Australian National Blood Pressure study (ANBP2). Methods: This was an in- and post-trial observational study. About 4257 hypertensive participants aged 65 to 84 years within Australian family practices were randomized to an angiotensin-converting enzyme inhibitor or a diuretic treatment group. After excluding participants w..
View full abstractGrants
Awarded by Department of Physiology and Biophysics, University at Buffalo
Funding Acknowledgements
ANBP2 was funded by a joint venture of the Commonwealth Government of Australia, the National Health and Medical Research Council, Merck Sharp & Dohme, and academic institutions and the post-trial cohort by a Program Grant (546272) from the National Health and Medical Research Council. In the present study, the researchers gratefully acknowledge the RACGP Foundation and Therapeutic Guidelines Ltd for their support of this project.